VEA
APGE

Virtus ETF Advisers’s Apogee Therapeutics APGE Stock Holding History

Virtus ETF Advisers’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,604
Closed -$72.7K – 441
2024
Q4 		$72.7K Sell
1,604
-534
-25% -$27.2K 0.03% 355
2024
Q3 		$126K Buy
2,138
+39
+2% +$1.87K 0.06% 345
2024
Q2 		$82.6K Sell
2,099
-1,628
-44% -$79K 0.04% 391
2024
Q1 		$248K Sell
3,727
-257
-6% -$11.2K 0.13% 233
2023
Q4 		$111K Buy
+3,984
New +$79.9K 0.07% 328

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Virtus ETF Advisers's APGE Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Apogee Therapeutics (APGE) in Q1 2025, closing a stake of 1,604 shares — an estimated $72.7K sold.

Virtus ETF Advisers first reported a position in APGE in Q4 2023 and held it in 5 quarters. The position peaked at $248K in Q1 2024. 168 funds tracked by Wall St. Rank hold APGE as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Apogee Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,604 Apogee Therapeutics shares in Q1 2025, an estimated $72.7K.
  • Virtus ETF Advisers first reported a position in Apogee Therapeutics in Q4 2023 and held it in 5 quarters.
  • Virtus ETF Advisers's Apogee Therapeutics position peaked at $248K in Q1 2024.
  • 168 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.